A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
To evaluate the efficacy and safety TQB2102 for injection in the treatment of patients with Her2-positive biliary tract cancer.
Biliary Tract Cancer
DRUG: TQB2102 for injection
Incidence and severity of adverse events (AE) and serious adverse events (SAE), Any adverse medical event that occurred from the time the subject signed the informed consent until 28 days after the last dose/start of the new antitumor therapy (whichever came first)., From the time the subject signed the informed consent until 28 days after the last dose/start of the new antitumor therapy|Phase II Recommended Dose (RP2D), Phase II Recommended Dose (RP2D), Baseline up to 24 weeks
Objective response rate (ORR), The percentage of subjects achieving complete response (CR) or partial response (PR) as assessed by the investigator based on the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1., Baseline up to 36 weeks|Progression-free survival (PFS), The time between first medication and first disease progression or death from any cause., Baseline up to 36 weeks|Disease control rate (DCR), The first assessment was complete response, partial response, and time to disease stabilization., Baseline up to 36 weeks|Disease response time (DOR), First assessed as complete or partial response to first disease progression or time of death from all causes., Baseline up to 36 weeks|Overall survival (OS), Time from first use to death from any cause, Baseline up to 36 weeks
To evaluate the efficacy and safety TQB2102 for injection in the treatment of patients with Her2-positive biliary tract cancer.